References
- Hooper D C, Wolfson J S. Mode of action of the new quinolones: New data. Eur J Clin Microbiol Infect Dis 1991; 10: 223–231
- Bryan L E, Bedard J. Impermeability to quinolones in Gram-positive and Gram-negative bacteria. Eur J Clin Microbiol Infect Dis 1991; 10: 232–239
- Bryan L E, Bedard J, Chamberland S, Wong S. Quinolone antimicrobial agents: mechanism of action and resistance development. Clin Invest Med 1989; 12: 14–19
- Baker C N, Stocker S A, Culver D H, Thornsberry C. Comparison of the E-test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J Clin Microbiol 1991; 29: 533–538
- George R C, Ball L C, Norbury P B. Susceptibility to ciprofloxacin of nosocomial Gram-negative bacteria and staphylococci isolated in the UK. J Antimicrob Chemother 1990; 26(Suppl F)145–156
- Endtz H P, Ruijs G J, van Klingeren B, Jansen W H, van der Reyden T, Mouton R P. Quinolone resistance in campylobacter isolated from man and poultry following the introduction of fluoroqunolones in veterinary medicine. J Antimicrob Chemother 1991; 27: 199–208
- Wretlind B, Strömberg A, Östlund L, Sjögren E, Kaijser B. Rapid emergence of quinolone resistance in Campylobacter jejuni in patients treated with norfloxacin. Scand J Infect Dis 1992; 24: 685–686
- Lopez-Brea M, Alarcon T. Isolation of fluoroquinolone-resistant Escherichia coli and Klebsiella pneumoniae from an infected Hickman catheter. Eur J Clin Microbiol Infect Dis 1990; 9: 345–347
- Jonsson M, Walder M, Forsgren A. First clinical isolate of highly fluoroquinolone-resistant Escherichia coli in Scandinavia. Eur J Clin Microbiol Infect Dis 1990; 9: 851–853
- Neringer R, Forsgren A, Hansson C, Ode B, the South Swedish Lolex study group. Lomefloxacin versus norfloxacin in the treatment of uncomplicated urinary tract infections: threeday versus seven-day treatment. Scand J Infect Dis 1992; 24: 773–780